Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 1, 2012, Pages 16-23

  Gupta, Shivangi ^a   Wulf, Gerald ^a   Henjakovic, Maja ^a   Koepsell, Hermann ^b   Burckhardt, Gerhard ^a   Hagos, Yohannes ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PYRIDINIUM IODIDE; ABC TRANSPORTER; BENDAMUSTINE; BUSULFAN; CATION; CHLORAMBUCIL; CLADADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; ETOPOSIDE; FLUDARABINE; FLUOROADENINE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MELPHALAN; MESSENGER RNA; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 4; ORGANIC CATION TRANSPORTER 1; PACLITAXEL; TREOSULFAN; TROFOSFAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CATION TRANSPORT; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG BINDING; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN CELL; LEUKEMIA CELL; LYMPHOMA CELL; LYMPHOMA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STABLE TRANSFECTION;

ANIMALS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA; ORGANIC CATION TRANSPORTER 1; PACLITAXEL;

EID: 84863363910     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.190561     Document Type: Article

References (27)

1. Bahn A, Hagos Y, Reuter S, Balen D, Brzica H, Krick W, Burckhardt BC, Sabolic I, and Burckhardt G (2008) Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13). J Biol Chem 283:16332-16341.
2. Bergeron MJ, Simonin A, Bürzle M, and Hediger MA (2008) Inherited epithelial transporter disorders-an overview. J Inherit Metab Dis 31:178-187.
3. Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, Mahjoubi M, Hérait P, Armand JP, and Bugat R (1995) Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 6:141-151.
4. Ciarimboli G, Ludwig T, Lang D, Pavenstädt H, Koepsell H, Piechota HJ, Haier J, Jaehde U, Zisowsky J, and Schlatter E (2005) Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 167:1477-1484. (Pubitemid 41713303)
5. Fischer GA (1962) Detective transport of amethopterin (methotrexate) as a mechanism of resistance to the antimetabolite in L5178Y leukemic cells. Biochem Pharmacol 11:1233-1234.
6. Halwachs S, Schaefer I, Seibel P, and Honscha W (2011) Antiepileptic drugs reduce the efficacy of methotrexate chemotherapy through accelerated degradation of the reduced folate carrier by the ubiquitin-proteasome pathway. Chemotherapy 57: 345-356.
7. Halwachs S, Schäfer I, Seibel P, and Honscha W (2009) Antiepileptic drugs reduce efficacy of methotrexate chemotherapy by downregulation of Reduced folate carrier transport activity. Leukemia 23:1087-1097.
8. Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, and Bruford EA (2004) The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch 447:465-468. (Pubitemid 38241432)
9. Huang Y (2007) Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev 26:183-201.
10. Kim DH, Park JY, Sohn SK, Lee NY, Baek JH, Jeon SB, Kim JG, Suh JS, Do YR, and Lee KB (2006) Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int J Cancer 118:2195-2201.
11. Koepsell H, Lips K, and Volk C (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24:1227-1251. (Pubitemid 46876495)
12. Matherly LH, Hou Z, and Deng Y (2007) Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 26:111-128. (Pubitemid 46452186)
13. More SS, Li S, Yee SW, Chen L, Xu Z, Jablons DM, and Giacomini KM (2010) Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. Mol Cancer Ther 9:1058-1069.
14. Okabe M, Unno M, Harigae H, Kaku M, Okitsu Y, Sasaki T, Mizoi T, Shiiba K, Takanaga H, Terasaki T, et al. (2005) Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun 333:754-762. (Pubitemid 40854224)
15. Rowinsky EK and Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332:1004-1014.
16. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914.
17. Schnedler N, Burckhardt G, and Burckhardt BC (2011) Glyoxylate is a substrate of the sulfate-oxalate exchanger, sat-1, and increases its expression in HepG2 cells. J Hepatol 54:513-520.
18. Shang T, Uihlein AV, Van Asten J, Kalyanaraman B, and Hillard CJ (2003) 1-Methyl- 4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter 3. J Neurochem 85:358-367. (Pubitemid 36438331)
19. Shnitsar V, Eckardt R, Gupta S, Grottker J, Müller GA, Koepsell H, Burckhardt G, and Hagos Y (2009) Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res 69:1494-1501.
20. Sonnichsen DS and Relling MV (1994) Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 27:256-269. (Pubitemid 24315086)
21. Toffoli G, Cecchin E, Corona G, and Boiocchi M (2003) Pharmacogenetics of irinotecan. Curr Med Chem Anticancer Agents 3:225-237. (Pubitemid 36512032)
22. Tsuji A (2002) Transporter-mediated Drug Interactions. Drug Metab Pharmacokinet 17:253-274.
23. Wessler I, Roth E, Deutsch C, Brockerhoff P, Bittinger F, Kirkpatrick CJ, and Kilbinger H (2001) Release of non-neuronal acetylcholine from the isolated human placenta is mediated by organic cation transporters. Br J Pharmacol 134:951-956. (Pubitemid 33052153)
24. White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, Quinn SR, Manley PW, and Hughes TP (2006) OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108:697-704. (Pubitemid 44061372)
25. Wild MD, Walle UK, and Walle T (1995) Extensive and saturable accumulation of paclitaxel by the human platelet. Cancer Chemother Pharmacol 36:41-44.
26. Yang R, Qin J, Hoang BH, Healey JH, and Gorlick R (2008) Polymorphisms and methylation of the reduced folate carrier in osteosarcoma. Clin Orthop Relat Res 466:2046-2051.
27. Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, et al. (2006) Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 66:8847-8857. (Pubitemid 44449203)